Design Therapeutics (NASDAQ:DSGN) Announces Earnings Results

Design Therapeutics (NASDAQ:DSGN) issued its quarterly earnings data on Monday. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02, Yahoo Finance reports.

Design Therapeutics Price Performance

Shares of DSGN stock traded down $0.21 during trading hours on Wednesday, hitting $4.00. The stock had a trading volume of 98,478 shares, compared to its average volume of 238,205. Design Therapeutics has a one year low of $1.94 and a one year high of $7.83. The stock’s 50-day moving average price is $3.99 and its two-hundred day moving average price is $3.55. The stock has a market capitalization of $225.98 million, a price-to-earnings ratio of -3.88 and a beta of 1.83.

Wall Street Analyst Weigh In

Several equities analysts recently commented on DSGN shares. Piper Sandler raised shares of Design Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $6.00 to $12.00 in a research note on Tuesday, May 7th. Royal Bank of Canada restated a “sector perform” rating and issued a $4.00 price objective on shares of Design Therapeutics in a report on Tuesday. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $6.60.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.